In 2023, the pharmaceutical industry will continue to set off a wave of cooperation!

【Pharmaceutical Network Market Analysis】Pharmaceutical companies have always been very common in the industry, and at the beginning of 2023, the pharmaceutical industry has set off a wave
of cooperation.
Among them, the "marriage" of pharmaceutical companies in the cooperative development of new drugs is constantly emerging
.
On January 3, Biocytogen (Beijing) Pharmaceutical Technology Co.
, Ltd.
announced that it signed a cooperation, transfer and exclusive license agreement
for antibody drug molecules with Hansen Pharmaceutical Group Co.
, Ltd.
Biocytogen licenses Hansen Pharmaceutical's selected fully human antibody molecules for the development, manufacturing and commercialization
of drugs worldwide.
Under the agreement, Biocytogen will receive a down payment, milestone payments for different development stages and commercialization, up to hundreds of millions of dollars; In the future, it will also receive a single-digit net sales share
based on products.
Biocytogen is an international biotechnology company that drives the research and development of new drugs with innovative technology, currently based on the self-developed and completely independent intellectual property rights of the fully human antibody RenMice® platform (RenMab®, RenLite® and RenNano® mice), Biocytogen has integrated monoclonal antibody, bispecific antibody and nanobody development technology platform, animal in vivo efficacy screening platform, and strong clinical development capabilities to form a unique, New drug R&D capabilities
covering the whole process of drug development.
It is reported that Biocytogen is conducting large-scale drug development for more than 1,000 potentially druggable targets ("Thousand Mouse AntibodiesTM" program), and with the implementation of the plan, it has signed 28 drug cooperation development agreements and reached RenMice® platform licensing cooperation
with 16 companies, including a number of MNC.
It is understood that before that, Biocytogen provided Hansen Pharmaceutical with candidate fully human antibody molecules for its selected targets generated by the "Thousand Mouse AntibodiesTM" project, and Hansen Pharmaceutical exercised the right to choose after completing the evaluation of candidate antibody molecules to reach the license agreement
.
In addition to the above cooperation, on January 3, Propharma announced that the company and Simcere Pharmaceutical also signed a strategic cooperation framework agreement to carry out long-term cooperation
in CDMO projects.
The signing of the strategic cooperation framework agreement does not involve specific cooperation projects, which will not have a significant impact on the company's operating performance this year, and if the subsequent specific business can be smoothly advanced as planned, it will have a positive impact
on the company's future business performance.
Of course, through cooperation, many companies have begun to usher in new progress
in research and development.
For example, on January 2, Junshi Biologics announced that the oral nucleoside anti-SARS-CoV-2 drug VV116 tablets, jointly developed by its holding subsidiary Juntuo Biologics and Wangshan Wangshui, has completed a phase III clinical study comparing the combination drug of nematevir tablets/ritonavir tablets (PAXLOVID) for the early treatment of patients with mild to moderate novel coronavirus infection with progression to severe including high-risk factors for death.
At the same time, a number of international multi-center phase III clinical studies
of VV116 have been carried out in different populations.
Industry analysts believe that on the whole, cooperation is still an important path
for win-win research and development of new drugs.
In the context of pharmaceutical innovation becoming the general trend of industry development and market competition intensifying, pharmaceutical companies are expected to continue to set off a wave
of cooperation in 2023 in order to strengthen and expand R&D pipelines and accelerate the commercialization of products.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.